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The National Cholesterol Education Program’s AdultTreatment Panel III report (ATP III)1 identified the
metabolic syndrome as a multiplex risk factor for cardiovas-
cular disease (CVD) that is deserving of more clinical
attention. The cardiovascular community has responded with
heightened awareness and interest. ATP III criteria for met-
abolic syndrome differ somewhat from those of other orga-
nizations. Consequently, the National Heart, Lung, and Blood
Institute, in collaboration with the American Heart Associa-
tion, convened a conference to examine scientific issues
related to definition of the metabolic syndrome. The scientific
evidence related to definition was reviewed and considered
from several perspectives: (1) major clinical outcomes, (2)
metabolic components, (3) pathogenesis, (4) clinical criteria
for diagnosis, (5) risk for clinical outcomes, and (6) thera-
peutic interventions.
Clinical Outcomes of Metabolic Syndrome
ATP III viewed CVD as the primary clinical outcome of
metabolic syndrome. Most individuals who develop CVD
have multiple risk factors. In 1988, Reaven2 noted that
several risk factors (eg, dyslipidemia, hypertension, hyper-
glycemia) commonly cluster together. This clustering he
called Syndrome X, and he recognized it as a multiplex risk
factor for CVD. Reaven and subsequently others postulated
that insulin resistance underlies Syndrome X (hence the
commonly used term insulin resistance syndrome). Other
researchers use the term metabolic syndrome for this cluster-
ing of metabolic risk factors. ATP III used this alternative
term. It avoids the implication that insulin resistance is the
primary or only cause of associated risk factors. Although
ATP III identified CVD as the primary clinical outcome of
the metabolic syndrome, most people with this syndrome
have insulin resistance, which confers increased risk for type
2 diabetes. When diabetes becomes clinically apparent, CVD
risk rises sharply. Beyond CVD and type 2 diabetes, individ-
uals with metabolic syndrome seemingly are susceptible to
other conditions, notably polycystic ovary syndrome, fatty
liver, cholesterol gallstones, asthma, sleep disturbances, and
some forms of cancer.
Components of Metabolic Syndrome
ATP III1 identified 6 components of the metabolic syndrome
that relate to CVD:
● Abdominal obesity
● Atherogenic dyslipidemia
● Raised blood pressure
● Insulin resistance  glucose intolerance
● Proinflammatory state
● Prothrombotic state
These components of the metabolic syndrome constitute a
particular combination of what ATP III terms underlying,
major, and emerging risk factors. According to ATP III,
underlying risk factors for CVD are obesity (especially
abdominal obesity), physical inactivity, and atherogenic diet;
the major risk factors are cigarette smoking, hypertension,
elevated LDL cholesterol, low HDL cholesterol, family
history of premature coronary heart disease (CHD), and
aging; and the emerging risk factors include elevated triglyc-
erides, small LDL particles, insulin resistance, glucose intol-
erance, proinflammatory state, and prothrombotic state. For
present purposes, the latter 5 components are designated
metabolic risk factors. Each component of the metabolic
syndrome will be briefly defined.
● Abdominal obesity is the form of obesity most strongly
associated with the metabolic syndrome. It presents clini-
cally as increased waist circumference.
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● Atherogenic dyslipidemia manifests in routine lipoprotein
analysis by raised triglycerides and low concentrations of
HDL cholesterol. A more detailed analysis usually reveals
other lipoprotein abnormalities, eg, increased remnant li-
poproteins, elevated apolipoprotein B, small LDL particles,
and small HDL particles. All of these abnormalities have
been implicated as being independently atherogenic.
● Elevated blood pressure strongly associates with obesity
and commonly occurs in insulin-resistant persons. Hyper-
tension thus commonly is listed among metabolic risk
factors. However, some investigators believe that hyper-
tension is less “metabolic” than other metabolic-syndrome
components. Certainly, hypertension is multifactorial in
origin. For example, increasing arterial stiffness contrib-
utes significantly to systolic hypertension in the elderly.
Even so, most conference participants favored inclusion of
elevated blood pressure as one component of the metabolic
syndrome.
● Insulin resistance is present in the majority of people with
the metabolic syndrome. It strongly associates with other
metabolic risk factors and correlates univariately with
CVD risk. These associations, combined with belief in its
priority, account for the term insulin resistance syndrome.
Even so, mechanisms underlying the link to CVD risk
factors are uncertain, hence the ATP III’s classification of
insulin resistance as an emerging risk factor. Patients with
longstanding insulin resistance frequently manifest glucose
intolerance, another emerging risk factor. When glucose
intolerance evolves into diabetes-level hyperglycemia, el-
evated glucose constitutes a major, independent risk factor
for CVD.
● A proinflammatory state, recognized clinically by eleva-
tions of C-reactive protein (CRP), is commonly present in
persons with metabolic syndrome. Multiple mechanisms
seemingly underlie elevations of CRP. One cause is obe-
sity, because excess adipose tissue releases inflammatory
cytokines that may elicit higher CRP levels.
● A prothrombotic state, characterized by increased plasma
plasminogen activator inhibitor (PAI)-1 and fibrinogen,
also associates with the metabolic syndrome. Fibrinogen,
an acute-phase reactant like CRP, rises in response to a
high-cytokine state. Thus, prothrombotic and proinflamma-
tory states may be metabolically interconnected.
Pathogenesis of Metabolic Syndrome
The metabolic syndrome seems to have 3 potential etiological
categories: obesity and disorders of adipose tissue; insulin
resistance; and a constellation of independent factors (eg,
molecules of hepatic, vascular, and immunologic origin) that
mediate specific components of the metabolic syndrome.
Other factors—aging, proinflammatory state, and hormonal
changes—have been implicated as contributors as well.
Obesity and Abnormal Body Fat Distribution
ATP III considered the “obesity epidemic” as mainly respon-
sible for the rising prevalence of metabolic syndrome. Obe-
sity contributes to hypertension, high serum cholesterol, low
HDL cholesterol, and hyperglycemia, and it otherwise asso-
ciates with higher CVD risk. Abdominal obesity especially
correlates with metabolic risk factors. Excess adipose tissue
releases several products that apparently exacerbate these risk
factors. They include nonesterified fatty acids (NEFA), cyto-
kines, PAI-1, and adiponectin. A high plasma NEFA level
overloads muscle and liver with lipid, which enhances insulin
resistance. High CRP levels accompanying obesity may
signify cytokine excess and a proinflammatory state. An
elevated PAI-1 contributes to a prothrombotic state, whereas
low adiponectin levels that accompany obesity correlate with
worsening of metabolic risk factors. The strong connection
between obesity (especially abdominal obesity) and risk
factors led ATP III to define the metabolic syndrome essen-
tially as a clustering of metabolic complications of obesity.
Insulin Resistance
A second category of causation is insulin resistance. Many
investigators place a greater priority on insulin resistance than
on obesity in pathogenesis.2,3 They argue that insulin resis-
tance, or its accomplice, hyperinsulinemia, directly causes
other metabolic risk factors. Identifying a unique role for
insulin resistance is complicated by the fact that it is linked to
obesity. Insulin resistance generally rises with increasing
body fat content, yet a broad range of insulin sensitivities
exists at any given level of body fat.4 Most people with
categorical obesity (body mass index [BMI]30 kg/m2) have
postprandial hyperinsulinemia and relatively low insulin sen-
sitivity,5 but variation in insulin sensitivities exists even
within the obese population.4 Overweight persons (BMI 25 to
29.9 kg/m2) likewise exhibit a spectrum of insulin sensitivi-
ties, suggesting an inherited component to insulin resistance.
In some populations (eg, South Asians), insulin resistance
occurs commonly even with BMI 25 kg/m2 and apparently
contributes to a high prevalence of type 2 diabetes and
premature CVD. South Asians and others who manifest
insulin resistance with only mild-to-moderate overweight can
be said to have primary insulin resistance. Even with primary
insulin resistance, however, weight gain seems to enhance
insulin resistance and metabolic syndrome. Thus, dissociation
of obesity and primary insulin resistance in patients with
metabolic syndrome is difficult.
This is not to say that insulin resistance per se does not play
a significant role in causation of metabolic syndrome. When
insulin-resistant muscle is already overloaded with lipid from
high plasma NEFA levels, some excess NEFA presumably is
diverted to the liver, promoting fatty liver and atherogenic
dyslipidemia. Hyperinsulinemia may enhance output of very-
low-density lipoprotein triglycerides, raising triglycerides.
Insulin resistance in muscle predisposes to glucose intoler-
ance, which can be worsened by increased hepatic glucone-
ogenesis in insulin-resistant liver. Finally, insulin resistance
may raise blood pressure by a variety of mechanisms.
Independent Factors That Mediate Specific
Components of the Metabolic Syndrome
Beyond obesity and insulin resistance, each risk factor of the
metabolic syndrome is subject to its own regulation through
both genetic and acquired factors. This leads to variability in
expression of risk factors. Lipoprotein metabolism, for in-
stance, is richly modulated by genetic variation; hence,
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expression of dyslipidemias in response to obesity and/or
insulin resistance varies considerably. The same holds for
blood pressure regulation. Moreover, glucose levels depend
on insulin-secretory capacity as well as insulin sensitivity.
This variation in distal regulation cannot be ignored as an
important factor in causation of metabolic syndrome.
Other Contributing Factors
Advancing age probably affects all levels of pathogenesis,
which likely explains why prevalence of the metabolic
syndrome rises with advancing age.6 Recently, a proinflam-
matory state has been implicated directly in causation of
insulin resistance, as well as atherogenesis. Finally, several
endocrine factors have been linked to abnormalities in
body-fat distribution and hence indirectly to metabolic syn-
drome. Thus, pathogenesis of the metabolic syndrome is
complex and ripe with opportunities for further research.
Criteria for Clinical Diagnosis of
Metabolic Syndrome
At least 3 organizations have recommended clinical criteria
for the diagnosis of the metabolic syndrome.1,7–9 Their
criteria are similar in many aspects, but they also reveal
fundamental differences in positioning of the predominant
causes of the syndrome. Each will be reviewed briefly.
ATP III
Criteria of ATP III1 are shown in Table 1. When 3 of 5 of the
listed characteristics are present, a diagnosis of metabolic
syndrome can be made. The primary clinical outcome of
metabolic syndrome was identified as CHD/CVD. Abdomi-
nal obesity, recognized by increased waist circumference, is
the first criterion listed. Its inclusion reflects the priority
given to abdominal obesity as a contributor to metabolic
syndrome. Also listed are raised triglycerides, reduced HDL
cholesterol, elevated blood pressure, and raised plasma glu-
cose. Cutpoints for several of these are less stringent than
usually required to identify a categorical risk factor, because
multiple marginal risk factors can impart significantly in-
creased risk for CVD. Explicit demonstration of insulin
resistance is not required for diagnosis; however, most
persons meeting ATP III criteria will be insulin resistant.
Finally, the presence of type 2 diabetes does not exclude a
diagnosis of metabolic syndrome.
World Health Organization
In 1998, a World Health Organization (WHO) consultation
group outlined a provisional classification of diabetes that
included a working definition of the metabolic syndrome.7
This report was finalized in 1999 and placed on the WHO
website8 (see Table 2). The guideline group also recognized
CVD as the primary outcome of the metabolic syndrome.
However, it viewed insulin resistance as a required compo-
nent for diagnosis. Insulin resistance was defined as 1 of the
following: type 2 diabetes; impaired fasting glucose (IFG);
impaired glucose tolerance (IGT), or for those with normal
fasting glucose values (110 mg/dL), a glucose uptake below
the lowest quartile for background population under hyper-
insulinemic, euglycemic conditions. In addition to insulin
resistance, 2 other risk factors are sufficient for a diagnosis of
metabolic syndrome. A higher blood pressure was required
than in ATP III. BMI (or increased waist:hip ratio) was used
instead of waist circumference, and microalbuminuria was
listed as one criterion. The requirement of objective evidence
of insulin resistance should give more power to predict
diabetes than does ATP III, but like ATP III, the presence of
type 2 diabetes does not exclude a diagnosis of metabolic
syndrome. A potential disadvantage of the WHO criteria is
that special testing of glucose status beyond routine clinical
TABLE 1. ATP III Clinical Identification of the
Metabolic Syndrome
Risk Factor Defining Level
Abdominal obesity, given as waist circumference*†
Men 102 cm (40 in)





Blood pressure 130/85 mm Hg
Fasting glucose 110 mg/dL‡
*Overweight and obesity are associated with insulin resistance and the
metabolic syndrome. However, the presence of abdominal obesity is more
highly correlated with the metabolic risk factors than is an elevated BMI.
Therefore, the simple measure of waist circumference is recommended to
identify the body weight component of the metabolic syndrome.
†Some male patients can develop multiple metabolic risk factors when the
waist circumference is only marginally increased, eg, 94 to 102 cm (37 to 39
in). Such patients may have a strong genetic contribution to insulin resistance.
They should benefit from changes in life habits, similarly to men with
categorical increases in waist circumference.
‡The American Diabetes Association has recently established a cutpoint of
100 mg/dL, above which persons have either prediabetes (impaired fasting
glucose) or diabetes.14 This new cutpoint should be applicable for identifying
the lower boundary to define an elevated glucose as one criterion for the
metabolic syndrome.
TABLE 2. WHO Clinical Criteria for Metabolic Syndrome*
Insulin resistance, identified by 1 of the following:
● Type 2 diabetes
● Impaired fasting glucose
● Impaired glucose tolerance
● or for those with normal fasting glucose levels (110 mg/dL), glucose
uptake below the lowest quartile for background population under
investigation under hyperinsulinemic, euglycemic conditions
Plus any 2 of the following:
● Antihypertensive medication and/or high blood pressure (140 mm Hg
systolic or 90 mm Hg diastolic)
● Plasma triglycerides 150 mg/dL (1.7 mmol/L)
● HDL cholesterol 35 mg/dL (0.9 mmol/L) in men or 39 mg/dL
(1.0 mmol/L) in women
● BMI 30 kg/m2 and/or waist:hip ratio 0.9 in men, 0.85 in women
● Urinary albumin excretion rate 20 g/min or albumin:creatinine ratio
30 mg/g
*Derived from Alberti et al.7,8
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assessment may be necessary to diagnose metabolic
syndrome.
American Association of Clinical Endocrinologists
The American Association of Clinical Endocrinologists
(AACE)9 proposes a third set of clinical criteria for the
insulin resistance syndrome (Table 3). These criteria appear
to be a hybrid of those of ATP III and WHO metabolic
syndrome. However, no defined number of risk factors is
specified; diagnosis is left to clinical judgment. When a
person develops categorical diabetes, the term insulin resis-
tance syndrome no longer applies. In patients without IFG, a
2-hour postglucose challenge is recommended when an ab-
normality is clinically suspected. Finding abnormal 2-hour
glucose will improve prediction of type 2 diabetes.
Issue of Oral Glucose Tolerance Test
Both WHO and AACE include IGT, detected by oral glucose
tolerance test (OGTT) or 2-hour postglucose challenge,
among the risk factors for metabolic syndrome. ATP III did
not include it because of the added inconvenience and cost of
OGTT in clinical practice. Its added value for CVD risk
prediction appears small. However, several conference par-
ticipants suggested adding OGTT at the physician’s discre-
tion in nondiabetic patients with ATP III–defined metabolic
syndrome or 2 metabolic risk factors (Table 1). Several
potential benefits were noted. First, in the absence of IFG,
IGT could count as one metabolic risk factor defining
metabolic syndrome. If IGT were to be added to ATP III
criteria, metabolic syndrome prevalence over age 50 years
would increase by 5% (Table 4). Second, IGT carries
increased risk for type 2 diabetes. Third, postprandial hyper-
glycemia in a patient with IFG denotes diabetes, a high-risk
condition for CVD.
Metabolic Syndrome as a Risk Condition
It seems self-evident that a condition characterized by mul-
tiple risk factors will carry a greater risk for adverse clinical
outcomes than will a single risk factor. This conclusion is
implicit in Framingham risk equations, which incorporate
many of the components of the metabolic syndrome. For this
conference, Framingham investigators examined their exten-
sive database for the relation between metabolic syndrome
and future development of both CVD and diabetes. Their
analysis was carried out on 3323 Framingham offspring men
and women (mean age, 52 years) in 8 years of follow-up.
Metabolic Syndrome as a Predictor of CVD
Individuals with metabolic syndrome are at increased risk for
CHD.10 In Framingham, the metabolic syndrome alone pre-
dicted 25% of all new-onset CVD. In the absence of
diabetes, the metabolic syndrome generally did not raise
10-year risk for CHD to 20%; this is the threshold for ATP
III’s CHD risk equivalent. Ten-year risk in men with meta-
bolic syndrome generally ranged from 10% to 20%. Framing-
ham women with metabolic syndrome had relatively few
CHD events during the course of the 8-year follow-up; this
was due in part to the high proportion of women who were
under 50 years of age. Although the metabolic syndrome in
these women appeared to be accompanied by higher risk for
CVD/CHD, the confidence interval was wide, and differences
between those with and without metabolic syndrome were not
statistically significant. Of note, the 10-year risk for CHD in
most women in this relatively young cohort did not exceed 10%.
Framingham investigators then examined whether the met-
abolic syndrome carries incremental risk beyond the usual
risk factors of the Framingham algorithm. Analyses were
carried out both including and excluding patients with diabe-
tes. Several models were tested. Results were compared as C
statistics. The C statistic is the probability that the model used
will place a person in the right order, giving the higher
probability to the one who develops the disease than to the
one who does not. Some investigators consider this approach
to have limitations, particularly because of the high contribu-
tion of age alone to the C statistic. Nonetheless, this is a
standard method for evaluating the power of adding new risk
factors to multiple–risk factor equations. Various models
were tested. These included (1) the standard Framingham
algorithm,11 (2) ATP III metabolic syndrome risk factors
alone, (3) metabolic syndrome risk factors  age, (4) usual
Framingham risk factors  unique metabolic syndrome risk
factors (obesity, triglycerides, glucose), and (5) usual Fra-
mingham risk factors  metabolic syndrome as a single
variable. When usual risk factors and unique metabolic
syndrome risk factors were combined, either on a continuous
or categorical basis, the reliability of prediction (C statistic)
increased only marginally. The results of this analysis indi-
cated that no advantage is gained in risk assessment by
adding the unique risk factors of the ATP III metabolic
syndrome to the usual Framingham risk factors in risk
assessment. It is likely that most of the risk associated with
the metabolic syndrome is captured by age, blood pressure,
total cholesterol, diabetes, and HDL cholesterol. Beyond
these, obesity, triglycerides, and glucose levels (in the ab-
sence of diabetes) provided little additional power of predic-
tion. Repetition of the analysis including patients with diabe-
tes had little impact on the C statistic. Serum CRP possibly
TABLE 3. AACE Clinical Criteria for
Diagnosis of the Insulin Resistance Syndrome*
Risk Factor Components Cutpoints for Abnormality
Overweight/obesity BMI 25 kg/m2
Elevated triglycerides 150 mg/dL (1.69 mmol/L)
Low HDL cholesterol
Men 40 mg/dL (1.04 mmol/L)
Women 50 mg/dL (1.29 mmol/L)
Elevated blood pressure 130/85 mm Hg
2-Hour postglucose challenge 140 mg/dL
Fasting glucose Between 110 and 126 mg/dL





Ethnic groups having high risk for type
2 diabetes or CVD
*Diagnosis depends on clinical judgment based on risk factors.
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has independent predictive power beyond usual risk factors
and/or metabolic syndrome; however, the absolute increment
in risk associated with elevated CRP has not been adequately
tested.
Metabolic Syndrome as a Predictor of Diabetes
When the risk for new-onset diabetes was examined for the
Framingham cohort, in both men and women, the presence of
metabolic syndrome was highly predictive of new-onset
diabetes. Almost half of the population-attributable risk for
diabetes could be explained by the presence of ATP III
metabolic syndrome.
Diabetes as a Predictor of CVD
Framingham data showed that most men with diabetes had a
10-year risk for CHD 20%; in contrast, women rarely
exceeded the 20% level. Some authorities believe that im-
proved risk assessment in individuals with diabetes would be
clinically useful in risk management. Oxford investigators
therefore have developed a risk engine (available on the
World Wide Web)12 based on the large UK Prospective
Diabetes Study (UKPDS) database, which had 500 hard
CHD events. It differs from the Framingham algorithm in that
it includes a measure of glycemia and duration of diabetes.
Surveys of other diabetic populations by UKPDS investiga-
tors found that Framingham equations considerably underes-
timate risk for CHD and stroke, whereas the UKPDS Risk
Engine provides a more robust estimate.
Therapeutic Implications
Obesity and Body Fat Distribution as Targets
of Therapy
ATP III recommended that obesity be the primary target of
intervention for metabolic syndrome. First-line therapy
should be weight reduction reinforced with increased physi-
cal activity. Weight loss lowers serum cholesterol and triglyc-
erides, raises HDL cholesterol, lowers blood pressure and
glucose, and reduces insulin resistance. Recent data further
show that weight reduction can decrease serum levels of CRP
and PAI-1. Most conference participants held that obesity
contributes significantly to development of the metabolic
syndrome in the general population. They further acknowl-
edged that clinical management should focus first on lifestyle
changes—particularly weight reduction and increased exer-
cise. Even participants who emphasized the role of insulin
resistance in the pathogenesis of the metabolic syndrome
acknowledged that therapeutic lifestyle changes deserve pri-
ority. Some participants questioned whether such changes
could successfully be implemented in clinical practice. Still,
the potential for benefit certainly exists; implementation is
the challenge.
Insulin Resistance as Target of Therapy
If insulin resistance, whether primary or secondary to obesity,
is in the chain of causation of metabolic syndrome, it would
be an attractive target. Certainly, weight reduction and
increased physical activity will reduce insulin resistance.
Insulin resistance as a target has caught the imagination of the
pharmaceutical industry, and drug discovery is underway.
Two classes of drugs are currently available that reduce
insulin resistance. These are metformin and insulin sensitizers
such as thiazolidinediones (TZDs).
Metformin has long been used for treatment of type 2
diabetes. In UKPDS, metformin apparently reduced new-
onset CHD in obese patients with diabetes. In the Diabetes
Prevention Program, metformin therapy prevented (or de-
layed) onset of type 2 diabetes in persons with IGT. There
are, however, no CVD end-point studies on metformin-
treated patients with metabolic syndrome. Thus, at present,
metformin cannot be recommended for the express purpose
of reducing risk for CVD in persons with the metabolic
syndrome.
TZDs currently are approved for treatment of type 2
diabetes. They reduce insulin resistance, favorably modify
several metabolic risk factors, and reverse abnormal arterial
responses. Nonetheless, no clinical trial data yet exist to
document benefit in CVD risk reduction. Thus, in spite of
promise, TZDs cannot be recommended at present for pre-
venting CVD in patients with either metabolic syndrome or
diabetes.
Specific Metabolic Risk Factors as Targets
of Therapy
Atherogenic Dyslipidemia
Although statins typically are recognized to be LDL-lowering
drugs, they reduce all apolipoprotein B–containing lipopro-
teins. Recent subgroup analyses of statin trials reveal that
statins reduce risk for CVD events in patients with metabolic
syndrome. Fibrates also favorably modify atherogenic dys-
lipidemia and may directly reduce atherogenesis. Post hoc
analysis of recent fibrate trials strongly suggests that they
reduce CVD end points in patients with atherogenic dyslip-
idemia and metabolic syndrome.13 Moreover, clinical studies
demonstrate that abnormal lipoprotein patterns are doubly
improved by combined statin-fibrate therapy, but just how
TABLE 4. Impact on Prevalence of Metabolic Syndrome
if Impaired Glucose Tolerance Plus 2 or More Risk Factors












Non-Hispanic white 38.2 43.6
Non-Hispanic black 34.6 38.9







*Data derived from NHANES III. Data analysis provided by Dr Steven Haffner.
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much this combination reduces CVD events beyond statins
alone awaits demonstration with controlled clinical trials.
Elevated Blood Pressure
There is full agreement that hypertensive patients with
metabolic syndrome deserve lifestyle therapies to reduce
blood pressure. In addition, antihypertensive drugs should be
used as recommended by hypertension guidelines. No class of
antihypertensive drugs has been identified as being uniquely
efficacious in patients with metabolic syndrome.
Prothrombotic State
No drugs are available that target PAI-1 and fibrinogen. An
alternative approach to the prothrombotic state is antiplatelet
therapy. For example, low-dose aspirin reduces CVD events
in both secondary and primary prevention. Thus, use of
aspirin for primary prevention in patients with metabolic
syndrome is promising. According to current recommenda-
tions, low-dose aspirin therapy has a favorable efficacy/side
effect ratio when 10-year risk for CHD is 10%.
Proinflammatory State
There is growing interest in development of drugs to dampen
the proinflammatory state. Several lipid-lowering drugs will
reduce CRP levels, which could reflect an antiinflammatory
action.
Hyperglycemia
When patients with metabolic syndrome develop type 2
diabetes, they are at high risk for CVD. All CVD risk factors
should be intensively reduced. In addition, glucose levels
should be appropriately treated with lifestyle therapies and
hypoglycemic agents as needed to keep hemoglobin A1c
levels below guideline targets.
Conclusions
Conference participants agreed that CVD is the primary
clinical outcome of metabolic syndrome. Additionally, risk
for type 2 diabetes is higher, and diabetes is a major risk
factor for CVD. ATP III criteria provide a practical tool to
identify patients at increased risk for CVD. WHO and AACE
criteria require further oral glucose testing if IFG and diabetes
are absent. IGT on OGTT denotes greater risk for diabetes
than does metabolic syndrome without elevated fasting glu-
cose. Several potential benefits make OGTT in such patients
an attractive option for use at the discretion of the physician.
First, in the absence of IFG, IGT could count as one
metabolic risk factor defining metabolic syndrome, besides
carrying increased risk for type 2 diabetes. Moreover, post-
prandial hyperglycemia in a patient with IFG denotes diabe-
tes, a high-risk condition for CVD.
Regardless of diagnostic criteria used, there is full agree-
ment that therapeutic lifestyle change, with emphasis on
weight reduction, constitutes first-line therapy for metabolic
syndrome. Drug treatment to directly reduce insulin resis-
tance is promising, but clinical trials to prove reduction of
CVD are lacking. In patients in whom lifestyle changes fail to
reverse metabolic risk factors, consideration should be given
to treating specific abnormalities in these risk factors with
drugs. Use of drugs to target risk factors should be in accord
with current treatment guidelines.
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